<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367911</url>
  </required_header>
  <id_info>
    <org_study_id>122-0551-305</org_study_id>
    <nct_id>NCT02367911</nct_id>
  </id_info>
  <brief_title>A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study has been designed to determine and compare the efficacy and safety of
      122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque
      psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</measure>
    <time_frame>Day 15</time_frame>
    <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</measure>
    <time_frame>Day 15</time_frame>
    <description>A static assessment of the overall or &quot;average&quot; degree of severity of each of three key characteristics present within all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Subjects With IGA &quot;Treatment Success&quot;</measure>
    <time_frame>Day 8</time_frame>
    <description>&quot;Treatment success&quot; and IGA as defined in the primary outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</measure>
    <time_frame>Day 8</time_frame>
    <description>&quot;Treatment success&quot; and clinical signs as defined in the secondary outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Pruritus Score</measure>
    <time_frame>Day 15</time_frame>
    <description>Pruritus scale will be used to assess the subjective and multidimensional experience of the subject's pruritus (itching) during the previous two weeks at Baseline and Day 15. Possible scores range from 5 (no pruritus) to 25 (most severe pruritus).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in % Body Surface Area (BSA) With Active Psoriasis</measure>
    <time_frame>Day 8 and Day 15</time_frame>
    <description>The investigator will use the assumption that 1% BSA is approximately equal to the surface area of the subject's palm and fingers, with the fingers extended yet grouped together, creating a flat oval-like surface area.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>122-0551 Foam, topically applied twice daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Foam, topically applied twice daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>122-0551 Foam</intervention_name>
    <description>122-0551 Foam applied twice daily to treat psoriasis</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Foam</intervention_name>
    <description>Vehicle Foam applied twice daily to treat psoriasis</description>
    <arm_group_label>Vehicle Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2%
             and no more than 12% affected body surface area.

          -  Subject has an Investigator's Global Assessment (IGA) score of at least three
             (moderate) at study start.

          -  If subject is a woman of childbearing potential, she must have a negative urine
             pregnancy test and agree to use an effective form of birth control for the duration of
             the study.

        Exclusion Criteria:

          -  Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

          -  Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.

          -  Subject has a physical condition which, in the investigator's opinion, might impair
             evaluation of plaque psoriasis, or which exposes the subject to an unacceptable risk
             by study participation.

          -  Subject has used any phototherapy (including laser), photo-chemotherapy or other forms
             of photo based therapy for the treatment of their psoriasis within 30 days prior to
             study start.

          -  Subject has used any systemic methotrexate, retinoids, systemic corticosteroids
             [including intralesional, intra-articular, and intramuscular corticosteroids],
             cyclosporine or analogous products within 90 days prior to study start.

          -  Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental
             therapy) within five half-lives of the biologic prior to study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Andrasfay</last_name>
    <role>Study Director</role>
    <affiliation>Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida d/b/a Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSearch Clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>August 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2018</results_first_posted>
  <disposition_first_submitted>February 16, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 17, 2017</disposition_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: January 2015 to August 2015
The location of clinical sites included dermatology clinics and clinical research centers.</recruitment_details>
      <pre_assignment_details>All subjects who met the entry criteria were randomized and enrolled into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>122-0551 Foam, topically applied twice daily for two weeks
122-0551 Foam: 122-0551 Foam applied twice daily to treat psoriasis</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Arm</title>
          <description>Vehicle Foam, topically applied twice daily for two weeks
Vehicle Foam: Vehicle Foam applied twice daily to treat psoriasis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline demographics is based on the Intent-To-Treat (ITT) population, defined as all enrolled subjects in the study who were randomized and dispensed the test article.</population>
      <group_list>
        <group group_id="B1">
          <title>Active Arm</title>
          <description>122-0551 Foam, topically applied twice daily for two weeks
122-0551 Foam: 122-0551 Foam applied twice daily to treat psoriasis</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Arm</title>
          <description>Vehicle Foam, topically applied twice daily for two weeks
Vehicle Foam: Vehicle Foam applied twice daily to treat psoriasis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="13.44"/>
                    <measurement group_id="B2" value="52.0" spread="13.75"/>
                    <measurement group_id="B3" value="52.2" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</title>
        <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the ITT population, defined as all enrolled participants who were randomized and dispensed the test article.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>122-0551 Foam, topically applied twice daily for two weeks
122-0551 Foam: 122-0551 Foam applied twice daily to treat psoriasis</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Vehicle Foam, topically applied twice daily for two weeks
Vehicle Foam: Vehicle Foam applied twice daily to treat psoriasis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</title>
          <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe).</description>
          <population>Analysis shown is based on the ITT population, defined as all enrolled participants who were randomized and dispensed the test article.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</title>
        <description>A static assessment of the overall or &quot;average&quot; degree of severity of each of three key characteristics present within all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the Intent-to-Treat (ITT) population, defined as all enrolled participants who were randomized and applied at least one dose of the test article. Missing data was imputed as failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>122-0551 Foam, topically applied twice daily for two weeks
122-0551 Foam: 122-0551 Foam applied twice daily to treat psoriasis</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Vehicle Foam, topically applied twice daily for two weeks
Vehicle Foam: Vehicle Foam applied twice daily to treat psoriasis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</title>
          <description>A static assessment of the overall or &quot;average&quot; degree of severity of each of three key characteristics present within all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
          <population>Analysis shown is based on the Intent-to-Treat (ITT) population, defined as all enrolled participants who were randomized and applied at least one dose of the test article. Missing data was imputed as failure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plaque Elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects With IGA &quot;Treatment Success&quot;</title>
        <description>&quot;Treatment success&quot; and IGA as defined in the primary outcome measure.</description>
        <time_frame>Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</title>
        <description>&quot;Treatment success&quot; and clinical signs as defined in the secondary outcome measure.</description>
        <time_frame>Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Pruritus Score</title>
        <description>Pruritus scale will be used to assess the subjective and multidimensional experience of the subject's pruritus (itching) during the previous two weeks at Baseline and Day 15. Possible scores range from 5 (no pruritus) to 25 (most severe pruritus).</description>
        <time_frame>Day 15</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in % Body Surface Area (BSA) With Active Psoriasis</title>
        <description>The investigator will use the assumption that 1% BSA is approximately equal to the surface area of the subject's palm and fingers, with the fingers extended yet grouped together, creating a flat oval-like surface area.</description>
        <time_frame>Day 8 and Day 15</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent Adverse Events (AEs) were collected from study Day 1 (enrollment/first dose) to study completion (Day 15) or participant termination. AEs that continued beyond completion/termination were followed until resolution or stabilization.</time_frame>
      <desc>The safety population included all participants enrolled in the study who were dispensed and applied the test article at least once; because the first dose of the test article was applied at the study site (Day 1), all participants (N=144) were included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>122-0551 Foam, topically applied twice daily for two weeks
122-0551 Foam: 122-0551 Foam applied twice daily to treat psoriasis</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Arm</title>
          <description>Vehicle Foam, topically applied twice daily for two weeks
Vehicle Foam: Vehicle Foam applied twice daily to treat psoriasis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trichorrhexis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review thirty days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>Therapeutics, Inc.</organization>
      <phone>858-571-1800</phone>
      <email>projectmanager@therapeuticsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

